Web Results

www.ncbi.nlm.nih.gov/pmc/articles/PMC2841755

Nov 11, 2009 ... 2008)] and one second-line [E3200 (Giantonio et al. ... to the 5-FU/LV plus bevacizumab arm was halted after an interim analysis (Hurwitz et al. .... cause appeared to be lower in bevacizumab-treated patients (<65 years 69 vs.

www.ncbi.nlm.nih.gov/pubmed/19144677

Jan 14, 2009 ... Hurwitz HI(1), Yi J, Ince W, Novotny WF, Rosen O. Author information: (1)Duke University Medical Center, Division of Hematology & Oncology, ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC5300250

Jun 30, 2016 ... From this, Hurwitz et al conducted a Phase III randomized trial. ... vs FOLFIRI with bevacizumab as first-line chemotherapy in patients with ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC4406914

2008], an irinotecan-based (AVF2107g) [Hurwitz and Kabbinavar, 2005] chemotherapy doublet ... 2010, 2014a] or FOLFIRI (CRYSTAL) [Van Cutsem et al. ..... [PubMed]; Cunningham D., Lang I., Marcuello E., Lorusso V., Ocvirk J., Shin D ., et al.

www.ncbi.nlm.nih.gov/pmc/articles/PMC2789349

Tournigand, et al. addressed this issue in a trial in which half the patients with ... from an analysis by Grothey, et al. of seven randomized phase III trials in advanced colorectal cancer .... (55) When comparing the effect of panitumumab vs. ... Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined ...